Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients

Current Medical Research and Opinion

Volumn 22, Issue 6, 2006, Pages 1045-1064

  Vom Dahl, Stephan ^a   Poll, Ludger ^b   Di Rocco, Maja ^c   Ciana, Giovanni ^d   Denes, Carmencita ^e   Mariani, Giuliano ^f   Maas, Mario ^g  

^a St Franziskus Hospital Koln   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c G GASLINI INSTITUTE   (Italy)

^d INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^e Clinica Pediatrie III   (Romania)

^f UNIVERSITY OF PISA   (Italy)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Bone disease; Enzyme replacement therapy; Gaucher disease; Imiglucerase; Monitoring

Indexed keywords

ALGLUCERASE; BIOCHEMICAL MARKER; IMIGLUCERASE; IODINE 123; RADIOISOTOPE; TECHNETIUM 99M; TECHNETIUM 99M SESTAMIBI; UNCLASSIFIED DRUG; XENON 133;

ARTICLE; BONE DISEASE; CELL INFILTRATION; CLINICAL PRACTICE; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME REPLACEMENT; EVIDENCE BASED MEDICINE; GAUCHER DISEASE; GERMANY; HUMAN; ITALY; LUMBAR SPINE; MEDLINE; MONITORING; NUCLEAR MAGNETIC RESONANCE IMAGING; OSSIFICATION; PEER REVIEW; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOGRAPHY; ROMANIA; SCORING SYSTEM; TREATMENT RESPONSE;

EID: 33745728033     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X104623     Document Type: Article

References (129)

1. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. J Am Med Assoc 1999;281:249-54
2. Christomanou H, Chabas A, Pampols T, Guardiola A. Activator protein deficient Gaucher's disease. A second patient with the newly identified lipid storage disorder. Klin Wochenschr 1989;67:999-1003
3. Brady RO, Kanfer JN, Shapiro D. Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's disease. Biochem Biophys Res Commun 1965;18:221-5
4. Gaucher PCE. De l'epithélioma primitif de la rate, hypertrophie idiopathique de la rate sans leucémie [MD Thesis]. Faculté de Médicine de Paris, Paris, France; 1882
5. Cox TM, Schofield JP. Gaucher's disease: clinical features and natural history. Bailliere's Clin Haematol 1997;10:657-89
6. Grabowski GA. Gaucher disease: gene frequencies and genotype/phenotype correlations. Genet Test 1997;1:5-12
7. Poorthuis BJ, Wevers RA, Kleijer WJ, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 1999;105:151-6
8. Pinto R, Caseiro C, Lemos M, et al. Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet 2004;12:87-92
9. Zimran A, Kay A, Gelbart T, et al. Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore) 1992;71:337-53
10. Maaswinkel-Mooij P, Hollak C, van Eysden-Plaisier M, et al. The natural course of Gaucher disease in The Netherlands: implications for monitoring of disease manifestations. J Inherit Metab Dis 2000;23:77-82
11. Sack Jr GH. Clinical diversity in Gaucher's disease. Johns Hopkins Med J 1980;146:166-70
12. Wenstrup RJ, Roca-Espiau M, Weinreb NJ, Bembi B. Skeletal aspects of Gaucher disease: a review. Br J Radiol 2002;75 (Suppl 1):A2-12
13. Kane PA, Meili-Vergani G, Williams R, Karani JB. Pseudotumours of hepatic imaging. Clin Radiol 1996;51:362-5
14. Mistry PK, Sirrs S, Chan A, et al. Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab 2002;77:91-8
15. Lachmann RH, Wight DG, Lomas DJ, et al. Massive hepatic fibrosis in Gaucher's disease: clinico-pathological and radiological features. Q J Med 2000;93:237-44
16. de Fost M, vom Dahl S, Weverling GJ, et al. Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis 2006;36:53-8
17. 99mTc-Sestamibi. J Nucl Med 2003;44:1253-62
18. Itzchaki M, Lebel E, Dweck A, et al. Orthopedic considerations in Gaucher disease since the advent of enzyme replacement therapy. Acta Orthop Scand 2004;75:641-53
19. Weinreb NJ, Aggio MC, Andersson HC, et al.; International Collaborative Gaucher Group (ICGG). Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol 2004;41(Suppl 5):15-22
20. Stowens DW, Teitelbaum SL, Kahn AJ, Barranger JA. Skeletal complications of Gaucher disease. Medicine (Baltimore) 1985;64:310-22
21. Elstein D, Itzchaki M, Mankin HJ. Skeletal involvement in Gaucher's disease. Bailliere's Clin Haematol 1997;10:793-816
22. Esplin JA, MCPherson EJ. Treatment of bone complications in patients with Gaucher disease. Gaucher Clin Perspectives 1994;2:7-11
23. Bembi B, Ciana G, Mengel E, et al. Bone complications in children with Gaucher disease. Br J Radiol 2002;75(Suppl 1): A37-A44
24. Brady RO. The sphingolipidoses. New Engl J Med 1966;275:312-8
25. Fratantoni JC, Hall CW, Neufeld EF. Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science 1968;162:570-2
26. Beutler E, Dale GL, Guinto DE, Kuhl W. Enzyme replacement therapy in Gaucher's disease: preliminary clinical trial of a new enzyme preparation. Proc Natl Acad Sci USA 1977;74:4620-3
27. Brady RO, Pentchev PG, Gal AE, et al. Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease. New Engl J Med 1974;291:989-93
28. Sly WS, Kaplan A, Achord DT, et al. Receptor-mediated uptake of lysosomal enzymes. Prog Clin Biol Res 1978;23:547-51
29. Furbish FS, Steer CJ, Krett NL, Barranger JA. Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. Biochim Biophys Acta 1981;673:425-34
30. Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency - macrophage-targeted glucocerebrosidase for Gaucher's disease. New Engl J Med 1991;324:1464-70
31. Grabowski GA, Barton NW, Pastores G, et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995;122:33-9
32. Germain DP. Gaucher's disease: a paradigm for interventional genetics. Clin Genet 2004;65:77-86
33. Futerman AH, Sussman JL, Horowitz M, et al. New directions in the treatment of Gaucher disease. Trends Pharmacol Sci 2004;25:147-51
34. Pastores GM, Barnett NL, Kolodny EH. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. Clin Ther 2005;27:1215-27
35. Cox TM, Aerts JM, Andria G, et al.; Advisory Council to the European Working Group on Gaucher Disease. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis 2003;26:513-26
36. European Medicines Agency. Summary of product characteristics. http://www.emea.eu.int/humandocs/Humans/EPAR/cerezyme/cerezyme.htm
37. Weinreb NJ, Charrow J, Andersson HC, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002;113:112-9
38. Pastores GM, Sibille AR, Grabowski GA. Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood 1993;82:408-16
39. Goldblatt J, Szer J, Fletcher JM, et al. Enzyme replacement therapy for Gaucher disease in Australia. Int Med J 2005;35:156-61
40. Poll LW, Maas M, Terk MR, et al. Response of Gaucher bone disease to enzyme replacement therapy. Br J Radiol 2002;75(Suppl 1):A25-A36
41. Rosenthal DI, Doppelt SH, Mankin HJ, et al. Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics 1995;96:629-37
42. Baldellou A, Andria G, Campbell PE, et al. Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr 2004;163:67-75
43. Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004;41 (Suppl 5):4-14
44. Andersson HC, Charrow J, Kaplan P, et al.; International Collaborative Gaucher Group, US Regional Coordinators. Individualization of long-term enzyme replacement therapy for Gaucher disease. Genet Med 2005;7:105-10.
45. Errata in: Genet Med 2005;7(6):460,
46. Genet Med 2005;7(7):514
47. Minchew JT, Dawson EG. The spine and Gaucher disease. Gaucher Clin Perspectives 1991;2:1-6
48. Cormier C. Markers of bone metabolism. Curr Opin Rheumatol 1995;7:243-8
49. Delmas PD, Eastell R, Garnero P, et al.; Committee of Scientific Advisors of the International Osteoporosis Foundation. The use of biochemical markers of bone turnover in osteoporosis. Osteoporosis Int 2000;11(Suppl 6)S2-S17
50. Seibel MJ, Woitge HW. Basic principles and clinical applications of biochemical markers of bone metabolism: biochemical and technical aspects. J Clin Densitom 1999;2:299-321
51. Bettica P, Taylor AK, Talbot J, et al. Clinical performances of galactosyl hydroxylysine, pyridinoline, and deoxypyridinoline in postmenopausal osteoporosis. J Clin Endocrinol Metab 1996;81:542-6
52. Watts NB. Clinical utility of biochemical markers of bone remodeling. Clin Chem 1999;45:1359-68
53. Drexler HG, Gignac SM. Characterization and expression of tartrate-resistant acid phosphatase (TRAP) in hematopoietic cells. Leukemia 1994;8:359-68
54. Hayman AR, Macary P, Lehner PJ, Cox TM. Tartrate-resistant acid phosphatase (Acp 5): identification in diverse human tissues and dendritic cells. J Histochem Cytochem 2001;49:675-84
55. Mankin HJ, Doppelt SH, Rosenberg AE, Barranger JA. In: Avioli LV, Krane SM, editors. Metabolic bone disease, 2nd ed. Philadelphia (PA): Saunders; 1990. p. 732-50
56. Fiore CE, Barone R, Pennisi P, et al. Bone ultrasonometry, bone density, and turnover markers in type 1 Gaucher disease. J Bone Miner Metab 2002;20:34-8
57. Ciana G, Martini C, Leopaldi A, et al. Bone marker alterations in patients with type 1 Gaucher disease. Calcif Tissue Int 2003;72:185-9
58. Pastores GM, Wallenstein S, Desnick RJ, Luckey MM. Bone density in Type 1 Gaucher disease. J Bone Miner Res 1996;11:1801-7
59. Hermann G, Goldblatt J, Levy RN, et al. Gaucher's disease type 1: assessment of bone involvement by CT and scintigraphy. Am J Roentgenol 1986;147:943-8
60. Drugan C, Jebeleanu G, Grigorescu-Sido P, et al. Biochemical markers of bone turnover as tools in the evaluation of skeletal involvement in patients with type 1 Gaucher disease. Blood Cells Mol Dis 2002;28:13-20
61. Ciana G, Addobbati R, Tamaro G, et al. Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy. J Inherit Metab Dis 2005;28:723-32
62. Schiffmann R, Mankin H, Dambrosia JM, et al. Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy. Blood Cells Mol Dis 2002;28:288-96
63. Wenstrup RJ, Bailey L, Grabowski GA, et al. Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood 2004;104:1253-7
64. van den Berg WB, Bresnihan B. Pathogenesis of joint damage in rheumatoid arthritis: evidence of a dominant role for interleukin-I. Bailliere's Best Pract Res Clin Rheumatol 1999;13:577-97
65. Chikanza I, Fernandes L. Novel strategies for the treatment of osteoarthritis. Expert Opin Investig Drugs 2000;9:499-510
66. Bataille R, Chappard D, Klein B. Mechanisms of bone lesions in multiple myeloma. Hematol Oncol Clin North Am 1992;6:285-95
67. Lust JA, Donovan KA. The role of interleukin-1 beta in the pathogenesis of multiple myeloma. Hematol Oncol Clin North Am 1999;13:1117-25
68. Allen MJ, Myer BJ, Khokher AM, et al. Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10. Q J Med 1997;90:19-25
69. Ishikawa H, Tsuyama N, Liu S, et al. Accelerated proliferation of myeloma cells by interleukin-6 cooperating with fibroblast growth factor receptor 3-mediated signals. Oncogene 2005;24:6328-32
70. Michelakakis H, Spanou C, Kondyli A, et al. Plasma tumor necrosis factor-a (TNF-a) levels in Gaucher disease. Biochim Biophys Acta 1996;1317:219-22
71. Lichtenstein M, Zimran A, Horowitz M. Cytokine mRNA in Gaucher disease. Blood Cells Mol Dis 1997;23:395-401
72. Moran MT, Schofield JP, Hayman AR, et al. Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K. Blood 2000;96:1969-78
73. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;3:23-35
74. Boven LA, van Meurs M, Boot RG, et al. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol 2004;122:359-69
75. Rosenbloom BE, Weinreb NJ, Zimran A, et al. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood 2005;105:4569-72
76. Altarescu G, Phillips M, Foldes AJ, et al. The interleukin-6 promoter polymorphism in Gaucher disease: a new modifier gene? Q J Med 2003;96:575-8
77. Altarescu G, Zimran A, Michelakakis H, Elstein D. TNF-alpha levels and TNF-alpha gene polymorphism in type I Gaucher disease. Cytokine 2005;31(2):149-52
78. Delaisse JM, Engsig MT, Everts V, et al. Proteinases in bone resorption: obvious and less obvious roles. Clin Chim Acta 2000;291:223-34
79. Everts V, Hou WS, Rialland X, et al. Cathepsin K deficiency in pycnodysostosis results in accumulation of non-digested phagocytosed collagen in fibroblasts. Calcif Tissue Int 2003;73:380-6
80. Simonaro CM, Haskins ME, Schuchman EH. Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab Invest 2001;81:1319-28
81. Simonaro CM, D'Angelo M, Haskins ME, Schuchman EH. Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr Res 2005;57:701-7
82. Pan C, Nelson MS, Reyes M, et al. Functional abnormalities of heparan sulfate in mucopolysaccharidosis-I are associated with defective biologic activity of FGF-2 on human multipotent progenitor cells. Blood 2005;106:1956-64
83. Poll LW, Koch JA, Willers R, et al. Correlation of bone marrow response with hematological, biochemical, and visceral responses to enzyme replacement therapy of nonneuronopathic (type 1) Gaucher disease in 30 adult patients. Blood Cells Mol Dis 2002;28:209-20
84. Czartoryska B, Tylki-Szymanska A, Gorska D. Serum chitotriosidase activity in Gaucher patients on enzyme replacement therapy (ERT). Clin Biochem 1998;31:417-20
85. Aguilera B, Ghauharali-van der Vlugt K, Helmond MT, et al. Transglycosidase activity of chitotriosidase: improved enzymatic assay for the human macrophage chitinase. J Biol Chem 2003;278:40911-6
86. Mankin HJ, Sims KB, Bove CM. Erlenmeyer flasking of a child's bones: a diagnostic puzzle. Am J Orthop 2005;34:393-5
87. Maas M, Poll LW, Terk MR. Imaging and quantifying skeletal involvement in Gaucher disease. Br J Radiol 2002;75(Suppl 1): A13-A24
88. Tran HA. Erlenmeyer flask. J Clin Endocrinol Metab 2004;89:4827-8
89. Vogler 3rd JB, Murphy WA. Bone marrow imaging. Radiology 1988;168:679-93
90. Foster K, Chapman S, Johnson K. MRI of the marrow in the paediatric skeleton. Clin Radiol 2004;59:651-73
91. Babyn PS, Ranson M, McCarville ME. Normal bone marrow: signal characteristics and fatty conversion. Magn Reson Imaging Clin North Am 1998;6:473-95
92. Rosenthal DI, Scott JA, Barranger J, et al. Evaluation of Gaucher disease using magnetic resonance imaging. J Bone Joint Surg Am 1986;68:802-8
93. Poll LW, Koch JA, vom Dahl S, et al. Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results. Skeletal Radiol 2001;9:496-503
94. Terk MR, Dardashti S, Liebman HA. Bone marrow response in treated patients with Gaucher disease: evaluation by T1-weighted magnetic resonance images and correlation with reduction in liver and spleen volume. Skeletal Radiol 2000;29:563-71
95. Vlieger EJ, Maas M, Akkerman EM, et al. Vertebra disc ratio as a parameter for bone marrow involvement and its application in Gaucher disease. J Comput Assisted Tomogr 2002;26:843-8
96. Maas M, van Kuijk C, Stoker J, et al. Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging - initial experience. Radiology 2003;229:554-61
97. Miller SP, Zirzow GC, Doppelt SH, et al. Analysis of the lipids of normal and Gaucher bone marrow. J Lab Clin Med 1996;127:353-8
98. Hollak C, Maas M, Akkerman E, et al. Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease. Blood Cells Mol Dis 2001;27:1005-12
99. Maas M, Hollak CE, Akkerman EM, et al. Quantification of skeletal involvement in adults with type I Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. Am J Roentgenol 2002;179:961-5
100. Johnson LA, Hoppel BE, Gerard EL, et al. Quantitative chemical shift imaging of vertebral bone marrow in patients with Gaucher disease. Radiology 1992;182:451-5
101. Ansari SM, Begum T, Siddique AB. Usefulness of bone mineral density measurement in menopausal woman: a study of 217 post menopausal women. Bangladesh Med Res Counc Bull 2004;30:25-30
102. Lebel E, Dweck A, Foldes AJ, et al. Bone density changes with enzyme therapy for Gaucher disease. J Bone Miner Metab 2004;22:597-601
103. Tran SD, Terk MR, Colletti PM. Proton MR spectroscopy of bone marrow: precision and reliability. Am J Roentgenol 2000;174(Suppl:60)
104. Pastores GM, Hermann G, Norton KI, et al. Regression of skeletal changes in type 1 Gaucher disease with enzyme replacement therapy. Skeletal Radiol 1996;25:485-8
105. Lorberboym M, Pastores GM, Kim CK, et al. Scintigraphic monitoring of reticuloendothelial system in patients with type 1 Gaucher disease on enzyme replacement therapy. J Nucl Med 1997;38:890-5
106. 99Tc-LDL scintigraphy suggested for monitoring the efficacy of ERT. Clin Genet 1997;52:7-11
107. Rosenthal DI, Barton NW, McKusick KA, et al. Quantitative imaging of Gaucher disease. Radiology 1992;185:841-5
108. Mistry PK, Wraight EP, Cox TM. Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease. Lancet 1996;348:1555-9
109. 99mTc-HMPAO images in Gaucher disease. Eur J Nucl Med 1996;23:466-70
110. Blocklet D, Abramowicz M, Scoutens A. Bone, bone marrow and MIBI Scintigraphic findings in Gaucher's disease 'bone crisis'. Clin Nucl Med 2001;26:865-9
111. Aharoni D, Krausz Y, Elstein D, et al. Tc-99m Sestamibi bone marrow scintigraphy in Gaucher disease. Clin Nucl Med 2002;27:503-9
112. 99mTc-Sestamibi. J Nucl Med 2003;44:253-1262
113. Data presented at: 'Gaucher disease: focus on skeletal complications', Gaslini Children's Hospital, Genoa, Italy, February 2005
114. Zimran A, Kay A, Gelbart T, et al. Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore) 1992;71:337-53
115. 99mTc-Sestamibi bone marrow scintigraphy in patients with Gaucher disease. J Nucl Med 2004;45(Suppl):79p [abstract]
116. Fischman SL, Elstein D, Sgan-Cohen H, et al. Dental profile of patients with Gaucher disease. BMC Oral Health. 2003;3:4
117. Niederau C, Rolfs A, vom Dahl S, et al. Diagnosis and therapy of Gaucher disease. Current recommendations of German therapy centers in the year 2000. Med Klin (Munich) 2001;96:32-9
118. Manz M, Riessen R, Poll L, et al. High-grade lymphoma mimicking bone crisis in Gaucher's disease. Br J Haematol 2001;113:191-3
119. vom Dahl S, Poll LW, Haussinger D. Clinical monitoring after cessation of enzyme replacement therapy in M. Gaucher. Br J Haematol 2001;113(4):1084-7
120. Toth J, Erdos M, Marodi L. Rebound hepatosplenomegaly in type 1 Gaucher disease. Eur J Haematol 2003;70:125-8
121. Migita M, Fukunaga Y, Ueda T, et al. Progression of bone disease without deterioration of hematological parameters in a child with Gaucher disease during low-dose glucocerebrosidase therapy. Nippon Ika Daigaku Zasshi 1994;61:633-7
122. Ueda T, Fukunaga Y, Migita M, et al. Improvement of bone disease with increased dose of glucocerebrosidase in a Gaucher disease patient who had a bone lesion presenting during low-dose enzyme replacement therapy. Acta Paediatr Jpn 1996;38:260-4
123. De Fost M, Hollak CE, Groener A, et al. Superior effects of high-dose enzyme supplementation therapy in type I Gaucher disease on bone marrow involvement and chitotriosidase levels: a two center retrospective analysis. Blood 2006 March 9; [epub ahead of print]
124. Figueroa ML, Rosenbloom BE, Kay AC, et al. A less costly regimen of alglucerase to treat Gaucher's disease. New Engl J Med 1992;327:1632-6
125. Elstein D, Abrahamov A, Itzchaki M, Zimran A. Commentary: low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease. Blood Cells Mol Dis 1998;24:303-5 [discussion 306-8]
126. Beutler E. Treatment regimens in Gaucher's disease. Lancet 1995;346:581-2
127. Kenet G, Hayek S, Mor M, et al. The 1226G (N370S) Gaucher mutation among patients with Legg-Calve-Perthes disease. Blood Cells Mol Dis 2003;31:72-4
128. Cox TM. Gaucher's disease - an exemplary monogenic disorder. Q J Med 2001;94:399-402
129. Maas M, Goldblatt J, Robertson P. Skeletal monitoring and preliminary results. Data presented at the Australian Gaucher Treaters' Meeting, Melbourne, Australia, August 2005